Business Context and Reporting Period
This Form 8-K filing by MIRA PHARMACEUTICALS, INC. (MIRA) reports a change in executive leadership. The report date is June 2, 2026, covering events effective June 6, 2026.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The only financial data disclosed relates to executive compensation:
- Compensation: The Company will pay $6,000 per month to the new fractional Chief Financial Officer.
Material Changes
Executive Departure: Alan Weichselbaum ceased serving as Chief Financial Officer effective June 6, 2026. The departure was not the result of any disagreement with the Company regarding operations, policies, or practices.
Executive Appointment: Andriy Mushak was appointed as the fractional Chief Financial Officer, effective June 6, 2026. Mr. Mushak is a CPA with over 20 years of experience in SEC reporting and will provide services through his firm, LMAM Consulting Group, LLC.
Guidance, Outlook, and Risks
The filing contains no guidance, outlook, or management commentary regarding future financial performance. No specific risks or contingencies were disclosed beyond the standard transition of financial leadership.
Investor Verification Checklist
- Verify the terms of the Consulting Agreement between MIRA Pharmaceuticals, Inc. and LMAM Consulting Group, LLC (Exhibit 10.1).
- Confirm the transition timeline for financial reporting responsibilities between the outgoing and incoming CFO.
- Review subsequent filings for any impact on the Company's internal controls over financial reporting due to the leadership change.